Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Source: View publication →
In patients with acute coronary syndrome, transradial access significantly reduced net adverse clinical events compared to transfemoral access at 1 year, while bivalirudin did not significantly improve composite ischemic or net clinical outcomes compared to unfractionated heparin.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MATRIX trial is a landmark study that cemented transradial access as the default Class I recommended approach for patients with acute coronary syndrome undergoing invasive management, due to its durable benefits in reducing bleeding and improving net clinical outcomes. Conversely, the trial shifted clinical momentum away from bivalirudin. Because bivalirudin failed to demonstrate a significant reduction in MACE or NACE compared to the much less expensive unfractionated heparin, guidelines deprioritized its routine use, reserving it primarily for patients at high risk of bleeding.
Historical Context
Historically, percutaneous coronary intervention (PCI) for ACS was performed via the transfemoral route using unfractionated heparin and glycoprotein IIb/IIIa inhibitors. This approach carried a high risk of access-site bleeding, which was independently associated with mortality. Earlier trials, such as RIVAL (which suggested a mortality benefit for transradial access in STEMI) and HORIZONS-AMI (which showed bleeding and mortality benefits for bivalirudin), highlighted alternative strategies. However, subsequent trials like HEAT-PPCI challenged bivalirudin's supremacy. The MATRIX trial was specifically designed as a large-scale, 2x2 factorial study to definitively settle these debates by concurrently testing bleeding-avoidance strategies (radial access and bivalirudin) in a broad ACS population.
Guided Discussion
High-yield insights from every perspective
How does minimizing access site bleeding through transradial access biologically and clinically translate to a reduction in all-cause mortality in patients with acute coronary syndrome?
Key Response
Students must understand that bleeding in ACS is not merely a nuisance; it leads to hemodynamic compromise, sympathetic nervous system activation, cessation of critical life-saving antiplatelet therapies, and subsequent ischemic events or death. Radial access mechanically allows for easy compressibility, preventing the hidden and often fatal retroperitoneal bleeds associated with femoral access.
Given the MATRIX trial's findings regarding bivalirudin versus unfractionated heparin, how should this influence your choice of systemic anticoagulation for an ACS patient heading to the cath lab, particularly when radial access is already planned?
Key Response
Residents should recognize that if bleeding risk is already heavily mitigated by radial access, the theoretical bleeding benefit of the more expensive bivalirudin is diminished. Its lack of superiority in composite ischemic outcomes compared to UFH makes UFH the standard, cost-effective choice for routine ACS cases.
The MATRIX trial demonstrated a net adverse clinical event and mortality benefit for radial over femoral access, but how does the 'radial paradox' apply to hemodynamically unstable patients or those in cardiogenic shock, and how does operator learning curve impact these outcomes?
Key Response
Fellows need to grapple with complex PCI scenarios. The patients at highest bleeding risk (e.g., shock) benefit the most from radial access, yet radial access is technically harder to obtain in hypotensive, peripherally vasoconstricted states. Interpreting MATRIX requires acknowledging that the survival benefit is highly dependent on operator proficiency and radial volume.
Should transradial access be the absolute default for all invasive ACS management at our institution based on the MATRIX data, and if so, how do we systematically maintain femoral access proficiency among our trainees for complex cases requiring large-bore access?
Key Response
Attendings must balance adopting the superior technique (radial) for patient safety and mortality benefit while recognizing the necessity of femoral skills for large-bore access devices (e.g., Impella, TAVR, complex CTOs). The teaching point is managing the unintended consequence of procedural skill attrition.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MATRIX trial utilized a 2x2 factorial design to simultaneously assess access site and anticoagulant choice. What are the statistical assumptions regarding the interaction between these two interventions, and how might a synergistic or sub-additive effect on bleeding outcomes complicate the interpretation of the marginal effects?
Key Response
Researchers must evaluate the assumption of independent effects in factorial designs. Since both radial access and bivalirudin primarily target bleeding reduction, sub-additive effects could occur (i.e., bivalirudin has no added benefit if radial access already prevents bleeding), potentially rendering the trial underpowered to detect a significant interaction term.
In reviewing the 1-year outcomes of the MATRIX trial, how does the open-label design for the access site allocation and the potentially asymmetric crossover rate between the radial and femoral groups threaten the internal validity of the mortality and MACE endpoints?
Key Response
Editors look for systematic bias. Open-label trials are subject to performance and detection bias. Furthermore, if crossover from radial to femoral was higher (due to radial spasm or anatomical failure) than femoral to radial, an intention-to-treat analysis might dilute the true effect of radial access, which a rigorous reviewer must flag.
Based on the definitive 1-year data from MATRIX showing a mortality benefit, should transradial access be universally designated as a Class I, Level of Evidence A recommendation for all ACS patients, and how does the lack of bivalirudin superiority reshape the algorithm for periprocedural anticoagulation in current ESC and ACC/AHA guidelines?
Key Response
Guideline committees evaluate whether data is robust enough to mandate a practice shift. MATRIX, alongside RIVAL, solidifies radial access as a Class I recommendation. Meanwhile, the lack of benefit for bivalirudin over UFH supports prioritizing UFH due to cost and similar efficacy, moving bivalirudin to an alternative status (Class IIa/IIb) in modern guidelines.
Clinical Landscape
Noteworthy Related Trials
HORIZONS-AMI Trial
Tested
Bivalirudin monotherapy
Population
Patients with STEMI undergoing primary PCI
Comparator
Unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor
Endpoint
Major bleeding and net adverse clinical events at 30 days
RIVAL Trial
Tested
Radial artery access
Population
Patients with acute coronary syndromes
Comparator
Femoral artery access
Endpoint
Composite of death, myocardial infarction, stroke, or non-CABG-related major bleeding at 30 days
HEAT-PPCI Trial
Tested
Unfractionated heparin
Population
Patients with STEMI undergoing primary PCI
Comparator
Bivalirudin
Endpoint
Major adverse cardiovascular events at 28 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis